ArticleLeukemia2018
TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells.
Abstract read
In one paragraph
Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.7field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- Article
- PROM1/CD133 marks a proliferative stem cell-like population of blasts in KMT2A rearranged infant ALL.Blood advances · 2025Article
- Significant Advancements and Evolutions in Chimeric Antigen Receptor Design.International journal of molecular sciences · 2024Review
- Proximal 4p Deletion Syndrome in an Infant With Multiple Systemic Anomalies.Molecular genetics & genomic medicine · 2024Article
- Aberrant stem cell and developmental programs in pediatric leukemia.Frontiers in cell and developmental biology · 2024Review
- Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia.Experimental hematology & oncology · 2023Article
- Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.Journal of translational medicine · 2023Review
- Review
- LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for mixed lineage leukemia-rearranged acute leukemia.Haematologica · 2022Article
- Article
- CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.Frontiers of medicine · 2021Review
- Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia.Experimental hematology · 2021Review
- Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.Frontiers of medicine · 2021Review
- Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Review
- Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.British journal of haematology · 2021Review
- An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia.Cancers · 2021Article
- Article
- Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion.Frontiers in immunology · 2021Article
- Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis.International journal of molecular sciences · 2020Review
- Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors.Oncogene · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Dan LiState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
Yutian HuState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
Zhen JinState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
You ZhaiState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
Yuting TanState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
Yan SunState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
Shouhai ZhuState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
Chunjun ZhaoState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
Bing ChenState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
Jiang ZhuState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
Zhu ChenState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
Saijuan ChenState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
Junmin LiState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China.
Han LiuState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Collaborative Innovation Center of Systems Biomedicine, Collaborative Innovation Center of Hematology, Shanghai 200025, China. liuhan68@sjtu.edu.cn.
Shanghai Institute of Hematology · CNShanghai Jiao Tong University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Immunotherapy, AdoptiveAC133 AntigenAnimalsAntigens, CD19BiomarkersCell Line, TumorCells, CulturedCytotoxicity, ImmunologicDisease Models, AnimalHistone-Lysine N-MethyltransferaseHumansImmunophenotypingLeukemia, Biphenotypic, AcuteMiceMyeloid-Lymphoid Leukemia ProteinReceptors, Antigen, T-CellAC133 AntigenAntigens, CD19BiomarkersHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinReceptors, Antigen, T-CellReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.